Navigation Links
University of Granada researchers identify changes in tumor cells that lead to metastasis
Date:1/17/2012

Researchers at the Centro de Genmica e Investigacin Oncolgica (GENYO) of which the University of Granada, Pfizer and the Andalusian Regional Government are members have identified the genetic and phenotypic changes that cause tumor progression and metastasis. The process of metastasis -which is the main cause of cancer death- is caused by tumor cells invading distant organs with no direct anatomical relationship with the organ originally affected. For this to happen, it is necessary that these cells which researchers call "circulating tumor cells" (CTCs) , travel to these organs through blood.

The researchers detected CTCs undergoing cell division in a breast cancer patient on systemic treatment. Thus, CTCs have been demonstrated both to be able to adapt to hostile microenvironments as blood, and to resist treatment and divide and proliferate in other organs and tissues, causing metastasis. So far, this behavior had not been observed in this type of microenvironments.

The results of this study were described in the article "Biodynamics of Circulating Tumor Cell, Tumor Microenvironment and Metastasis", published in the journals Cancer Biology & Therapy, Clinical Translational Oncoly y Annals of Oncology. The researchers found that breast cancer patients with circulating tumor cells (CTCs) at baseline tend to develop metastasis and have shorter disease-free survival after treatment. Thus, detecting CTCs during and after treatment allows physicians to identify which patients are responding favorably to chemotherapy. Consequently, patients with CTCs while receiving chemotherapy have shorter disease-free survival and lower overall survival rates. This is due to the fact that these cells are resistant to conventional treatments performed according to the genetic characteristics of the tumor. Therefore, CTCs can survive chemotherapy and produce metastasis to other organs.

More Efficient Individualized Treatments

University of Granada professor Jos Antonio Lorente -GENYO manager director and coordinator of the research group- affirms that the study of Circulating Tumor Cells (CTCs) is crucial "not only because they may be responsible for the development of metastasis, but also because they have genetic characteristics different to those found in the primary tumor and in metastatic cells. Such characteristics make these very aggressive cells resistant to the immunologic system and to the therapeutic agents generally used in cancer patients". Most of these treatments are targeted against proliferating tumor cells. Conversely, CTCs are found in a "dormant" phase, i.e. in a "non-proliferation" phase.

As these cells may indicate negative response to treatment, if they were isolated and genetically characterized, patients could be classified according to their chances of relapse, which would allow individualized follow-up.


'/>"/>
Contact: Dr. Jos Antonio Lorente Acosta. GENYO manager director
jlorente@ugr.es
34-958-637-079
University of Granada
Source:Eurekalert

Related medicine news :

1. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
2. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
3. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Smithsonian Institution, Arizona State University announce education and research partnership
6. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
7. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
8. Arizona State Universitys Decision Theater offers balance to an off-kilter world
9. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
10. Herzing University Online Launches Master and Bachelor of Science Degrees in Nursing
11. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology: